Cumulative viral titer reduction demonstrated by sequential challenge of a tangential flow membrane filtration system and a direct flow pleated filter cartridge

PDA Journal of Pharmaceutical Science and Technology

Volumn 51, Issue 5, 1997, Pages 208-212

  Aranha Creado, Hazel ^a   Fennington Jr , G J ^a,b  

^a PALL CORPORATION   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BACTERIOPHAGE; CONTROLLED STUDY; DRUG CONTAMINATION; MEMBRANE FILTER; MICROFILTRATION; PSEUDOMONAS SYRINGAE; ULTRAFILTRATION; VIRUS CONCENTRATION;

DRUG CONTAMINATION; ULTRAFILTRATION; VIRUSES;

EID: 0030661578     PISSN: 1076397X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Centers For Disease Control, "Hepatatis A among persons who received clotting factor concentrate - United States, September-December 1995," Morbid. Mortal. Weekly Rep. 45, 29-32 (1996).
2. R. D. Aach and R. A. Kahn, "Post-transfusion hepatitis: Current perspectives," Ann. Intern. Med. 92, 539-546 (1980).
3. Y. J. Wang, S. D. Lee, S. J. Hwang, C. Y. Chan, M. P. Chow, S. T. Lai, and K. J. Lo, "Incidence of post-transfusion hepatitis before and after screening for hepatitis C virus antibody," Vox Sang 67, 187-190 (1994).
4. S. C. Darby, D. W. Ewart, P. L. Giangrande, P. J. Dolin, R. J. D. Spooner, and C. R. Rizza, "Mortality before and after HIV infection in the complete UK population of hemophiliacs," Nature 377, 79-82 (1995).
5. S. Builder, R. Van Reis, N. Paoni, and J. Ogez, "Process Development and Regulatory Approval of Lisane-Type Plasminogen Activator," In: Advances in Animal Cell Biology and Technology for Bioprocesses. R. W. Spier, J. B. Griffiths, J. Stephenne, and P. J. Crooy (Eds), Butterworths, Stoneham, MA 452-464 (1989).
6. ICH harmonized tripartite guideline, "Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin," Step 4 Adoption Recommendation, pp. 1-27, IFPMA, Geneva, Switzerland (1997).
7. B. Horowitz, M. E. Wiebe, A. Lippin, and M. H. Stryker, "Inactivation of viruses in labile blood derivatives," Transfusion 25, 516-522 (1985).
8. J. K. Walter, W. Werz, and W. Berthold, "Virus Removal and Inactivation. Concept and data for process validation of downstream processing," Biotech Forum Eur. 9, 560-564 (1992).
9. H. W. Ackermann and L. Berthiaume, Atlas of Virus Diagrams, CRC Press, Inc., Boca Raton, FL, 1995, p. 33.
10. C. D. Lytle, S. C. Tondreau, W. Truscott, A. P. Budacz, R. K. Kuester, L. Venegas, R. E. Schmukler, and W. H. Cyr, "Filtration sizes of human immunodeficiency virus type 1 and surrogate viruses used to test barrier materials," Appl. Environ. Microbiol. 58, 747-749 (1992).
11. A. K. Vidaver, "Synthetic and complex media for the rapid detection of fluorescence of phytopathogenic pseudomonads: Effect of the carbon source," Appl. Microbiol. 15, 1523-1524 (1967).
12. D. B. Pall, "Quality control of absolute bacteria removal filters," Bull. PDA 29, 192-204 (1975).
13. Validation Guide for Pall Ultipor® VF™ DV50 Ultipleat™ AB style virus removal filter cartridges, Pall Ultrafine Filtration Company, Pall Corporation, East Hills, N.Y., 1995, Publication TR-695.
14. H. Aranha-Creado, K. Oshima, S. Jafari, G. Howard, Jr., and H. Brandwein, "Virus retention by Ultipor® VF™ Grade DV50 membrane filters," Scientific and Technical Report. STR-PUF-24, Pall Ultrafine Filtration Company, East Hills, N.Y. (1995).
15. J. A. L. Santos, M. Mateus, and J. M. S. Cabral, Pressure Driven Membrane Processes, In C. A. Costa and J. S. Cabral (Eds.), Chromatographic and Membrane Processes in Biotechnology, Kluwer Academic Publishers, Netherlands, pp. 177-205 (1991).